BPC-157 is studied across several preclinical domains: angiogenesis and vascular signaling (VEGFR2/eNOS), nitric oxide pathway modulation, tendon and ligament fibroblast migration, muscle-injury recovery, and MAPK/ERK1/2-linked wound-healing signaling
The Twelve Peptides Now Coming Off the Category 2 Restricted List Below is a clinical overview of the twelve peptides addressed by the April 2026 FDA action , organized by what patients typically ask them to do
This suggests that retatrutide does not just reduce energy intake (calories in) but actively increases energy output (calories out), a dual-modality influence that tirzepatide does not theoretically possess to the same degree
PE-22-28 raises seizure threshold concerns via TREK-1 blockade Evidence integrity : Dihexa has a retracted key publication
Limitations include small cohorts, short follow-up, heterogeneous peptide types and doses, and mixed endpoints
Since the study of LLPS and MLOs/BCs began after the IDP concept was generally accepted, a thorough consideration of this very important point is outside the scopes of this historical perspective